Phase II trial of Pemetrexed plus Gemcitabine in patients with advanced non-clear cell renal cell carcinoma

OBJECTIVE: To determine the clinical activity and toxicity of combination pemetrexed and gemcitabine for locally advance and metastatic non-clear cell renal cell carcinoma. METHODS: In this phase II study patients were treated with pemetrexed 500 mg/m(2) IV infusion over 10 minutes(min) on day one f...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Richey, Stephen L, Tamboli, Pheroze, Ng, Chaan S, Lin, E, Lim, Zita D, Araujo, John C, Jonasch, Eric, Sharma, Padmanee, Pagliaro, Lance C, Tannir, Nizar M
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882166/
https://ncbi.nlm.nih.gov/pubmed/22706175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3182546a91
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky